Fish Oil for Immune Function: Resolvins, SPMs and the Omega-3 Immune Evidence

Fish oil's immune relevance is often framed solely in terms of anti-inflammatory effects — reducing prostaglandin production and lowering CRP. While accurate, this framing misses what is arguably omega-3's most important immune mechanism: the production of specialised pro-resolving mediators (SPMs) — a family of lipid molecules that actively terminate inflammatory responses and restore immune homeostasis. In aging populations where this resolution function is specifically impaired, EPA and DHA supplementation addresses a fundamental immune regulatory deficit that no other common supplement targets.

The Immune Resolution Deficit: Why This Matters

Healthy immune function requires not just activation but resolution — the ability to mount a strong response and then efficiently return to baseline without chronic inflammatory damage. This resolution is not passive (inflammation simply fading away) but an active, molecularly programmed process driven by SPMs. In older adults, SPM production declines significantly — contributing to the chronic low-grade inflammation (inflammaging) that simultaneously suppresses adaptive immune responsiveness and damages tissues through sustained NF-kB-driven cytokine production.

EPA and DHA are the direct precursors to the four major SPM families: resolvins (from EPA and DHA), protectins (from DHA), maresins (from DHA), and lipoxins. Without adequate tissue EPA and DHA, SPM synthesis is rate-limited — and immune resolution is impaired regardless of other interventions.

Research: SPMs and Infection Resolution

Resolvin E1 (RvE1, from EPA) and Resolvin D1 (RvD1, from DHA) have been shown in multiple animal studies to significantly accelerate resolution of bacterial pneumonia, reduce lung injury during respiratory infection, and promote clearance of bacteria from infected sites — not by suppressing the immune response but by programming its efficient termination once pathogens are cleared. Protectin D1 (from DHA) specifically reduces influenza-induced lung pathology and mortality in animal models.

Human clinical evidence for SPM-mediated immune resolution is emerging — plasma resolvin and protectin levels are measurably increased by omega-3 supplementation, and higher EPA/DHA status correlates with faster recovery from acute infections in observational studies.

Research: Innate Immune Cell Function

EPA and DHA are incorporated into immune cell membranes — particularly in neutrophils, macrophages, dendritic cells, and NK cells — where they influence cell signalling, receptor function, and cytokine production:

• Neutrophils: Higher membrane EPA content improves neutrophil chemotaxis (directed movement toward infection sites) and phagocytic capacity while reducing excessive oxidative burst that damages surrounding tissue
• Macrophages: DHA promotes anti-inflammatory M2 macrophage polarisation and enhances phagocytic clearance of apoptotic cells (efferocytosis) — essential for tissue repair after infection
• NK cells: Omega-3 supplementation has been shown to increase NK cell cytotoxic activity in multiple human studies, with the mechanism involving membrane fluidity changes that improve receptor clustering and immunological synapse formation
• Dendritic cells: DHA alters dendritic cell cytokine production, promoting tolerogenic rather than inflammatory responses to commensal antigens while preserving responses to pathogenic signals

Research: Vaccine Response Enhancement

A RCT in older adults found omega-3 supplementation significantly improved antibody response to influenza vaccination — increasing both the magnitude and durability of the vaccine-induced antibody titre compared to placebo. A second study found DHA supplementation enhanced pneumococcal vaccine responses. These findings are clinically significant because older adults characteristically mount suboptimal vaccine responses due to immunosenescence — and omega-3 supplementation appears to partially restore vaccine immunogenicity.

Research: Respiratory Infection Outcomes

A large UK Biobank analysis found higher habitual fish consumption was significantly associated with lower risk of severe respiratory infections requiring hospitalisation. A meta-analysis examining omega-3 and infection outcomes found consistent associations between higher omega-3 status and reduced respiratory infection risk, though RCTs specifically powered for respiratory infection incidence as a primary endpoint remain limited. The mechanistic evidence (SPM production, NK cell activation, vaccine enhancement) provides strong biological plausibility for the observational associations.

Omega-3 and the Gut Immune Axis

EPA and DHA support gut immune function through multiple mechanisms: reducing intestinal inflammation via eicosanoid pathway modulation, supporting gut barrier integrity by improving the lipid composition of epithelial cell membranes, and modulating the gut microbiome toward beneficial species associated with healthy immune tone. A 6-week omega-3 supplementation study found significant increases in gut microbiome diversity and beneficial Bifidobacterium populations — connecting omega-3 to gut immune axis support.

Dosage for Immune Function

• Effective dose: 1.5-3g combined EPA+DHA daily. The SPM production evidence suggests higher EPA is particularly important — look for supplements with EPA:DHA ratio of at least 1.5:1
• Form: Triglyceride form (rTG) absorbs 70% better than ethyl ester — check label for form specification
• Timing: With the largest fat-containing meal for optimal absorption
• Quality: IFOS-certified for purity and freshness — oxidised fish oil generates lipid peroxides that may counteract immune benefits
• Index: The Omega-3 Index (red blood cell EPA+DHA percentage) is the most accurate measure of omega-3 status — target above 8% for immune optimisation